TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver by Weber, Susanne Nicole et al.
RESEARCH ARTICLE
TLR4 Deficiency Protects against Hepatic
Fibrosis and Diethylnitrosamine-Induced Pre-
Carcinogenic Liver Injury in Fibrotic Liver
Susanne Nicole Weber1, Annika Bohner1, Dianne H. Dapito2, Robert F. Schwabe2,
Frank Lammert1*
1 Department of Medicine II, Saarland University Medical Center, Homburg, Germany, 2 Department of




The development of hepatocellular carcinoma (HCC) is a common consequence of
advanced liver fibrosis but the interactions between fibrogenesis and carcinogenesis are
still poorly understood. Recently it has been shown that HCC promotion depends on Toll-
like receptor (TLR) 4. Pre-cancerogenous events can be modelled in mice by the adminis-
tration of a single dose of diethylnitrosamine (DEN), with HCC formation depending
amongst others on interleukin (IL) 6 production. Mice lacking the hepatocanalicular phos-
phatidylcholine transporter ABCB4 develop liver fibrosis spontaneously, resemble patients
with sclerosing cholangitis due to mutations of the orthologous human gene, and represent
a valid model to study tumour formation in pre-injured cholestatic liver. The aim of this study
was to investigate DEN-induced liver injury in TLR4-deficient mice with biliary fibrosis.
Methods
ABCB4-deficient mice on the FVB/NJ genetic background were crossed to two distinct
genetic backgrounds (TLR4-sufficient C3H/HeN and TLR4-deficient C3H/HeJ) for more
than 10 generations. The two congenic knockout and the two corresponding wild-type
mouse lines were treated with a single dose of DEN for 48 hours. Phenotypic differences
were assessed by measuring hepatic collagen contents, inflammatory markers (ALT, CRP,
IL6) as well as hepatic apoptosis (TUNEL) and proliferation (Ki67) rates.
Results
Hepatic collagen accumulation is significantly reduced in ABCB4-/-:TLR4-/-double-deficient
mice. After DEN challenge, apoptosis, proliferation and inflammatory markers are
decreased in TLR4-deficient in comparison to TLR4-sufficient mice. When combining
ABCB4 and TLR4 deficiency with DEN treatment, hepatic IL6 expression and proliferation
rates are lowest in fibrotic livers from the double-deficient line. Consistent with these effects,
selective digestive tract decontamination in ABCB4-/- mice also led to reduced tumor size
and number after DEN.
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Conclusion
This study demonstrates that liver injury upon DEN challenge depends on pre-existing fibro-
sis and genetic background. The generation of ABCB4-/: TLR4-/- double-deficient mice illus-
trates that TLR4-deficiency protects against hepatic injury in a preclinical mouse model of
chronic liver disease.
Introduction
Hepatic fibrosis represents a wound healing response to chronic liver damage and may lead to
cirrhosis and hepatocellular carcinoma (HCC) which is the sixth most common cancer and the
third cause of cancer-related deaths worldwide [1]. Liver fibrosis is commonly caused by envi-
ronmental factors such as viral infections or malnutrition but the fact that fibrosis and its con-
sequences differ between individuals with similar risk profiles [2] and the results of genome-
wide association studies [3,4] point to a genetic predisposition, most likely mediated by multi-
ple genes and their interaction with environmental factors.
Toll-like receptors (TLRs) belong to a large family of transmembrane proteins that recog-
nize pathogen-associated molecular patterns (PAMPs) and are involved in innate immune
responses [5,6]. In addition, they contribute to adaptive immune reactions and the regulation
of sterile inflammation and tissue regeneration as well as carcinogenesis [7–9]. TLRs also play
an important role in liver pathophysiology and chronic liver diseases, since the liver is con-
stantly exposed to a high amount of PAMPs [10–12]. Especially TLR4, responsible for detect-
ing lipopolysaccharide (LPS) from Gram-negative bacteria, has been shown to be expressed by
nearly all cell types of the liver including hepatocytes [13], Kupffer cells [14], stellate cells [15],
sinusoidal endothelial cells [16] and biliary epithelial cells [17]. In alcohol-induced liver injury,
the activation of Kupffer cells depends on TLR4 [18], and in non-alcoholic fatty liver disease
TLR4 deficiency reduces hepatic lipid accumulation and inflammation after a methionine-cho-
line-deficient diet [19]. Hepatic fibrosis and cirrhosis have been linked to TLR4, with TLR4-de-
ficient mice displaying less fibrosis in chemically (carbon tetrachloride, CCl4 or thioacetamide,
TAA) or bile duct ligation (BDL)-induced fibrosis models [20]. In addition, TLR4-dependent
participation in HCC has been demonstrated in mice, linking the promotion of liver carcino-
genesis to intestinal microbiota [21]. Of note, in humans, a single nucleotide variation in the
TLR4 gene is associated with protection against fibrosis progression [22,23].
All these studies have been performed in either TLR4 mutant or deficient mice, or in the set-
ting of chemical (CCl4) and surgical models (BDL). Although CCl4 and BDL are accepted mod-
els for the induction of fibrosis in mice and rats [2], they do not perfectly resemble the
situation in patients with progressive liver fibrosis. In normal liver, the hepatocanalicular trans-
porter ABCB4 (ATP-binding cassette transporter B4; a.k.a. MDR2 in mice and MDR3 in
humans) translocates phosphatidylcholine from the hepatocyte into bile [24]. Mice that lack
ABCB4 develop biliary fibrosis spontaneously [25]. Disruption of the transporter leads to toxic
bile and cholangio- and hepatocellular damage, resulting in progressive intrahepatic cholestasis
and sclerosing cholangitis [25]. First abnormalities in the liver are detected 3 weeks after birth
and the fibrotic phenotype appears in the whole liver after 12 weeks [26]. On certain genetic
backgrounds (129/Ola, FVB/N, BALB/c, C57BL/6), HCC formation has been reported between
6 and 18 months of age [26–28]. Differences in genetic backgrounds affect chronic hepatitis
and HCC formation. For example, ABCB4-deficient mice on the C57BL/6 genetic background
show less hepatic inflammation and HCC formation than on the FVB/N background [29].
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In the present study, we combined the two genetic mouse models to establish a novel pre-
clinical model for the analysis of TLR4 effects on liver fibrosis. ABCB4-deficient mice were
crossed into the TLR4-deficient C3H/HeJ and the corresponding TLR4-sufficient C3H/HeN
strains to obtain double-deficient and control lines, respectively. As first described by Poltorak
and co-workers, C3H/HeJ mice carry a mutated form of the Tlr4 gene (p.H712P) that results in
TLR4 deficiency and defective LPS signaling [30]. Therefore they have widely been used and
represent a valid model to study the effects of TLR4 deficiency throughout the organism [30].
As we also aimed to investigate the role of TLR4 with respect to very early cancerogenous
events we furthermore combined the ABCB4/TLR4-deficiency model with diethylnitrosamine
(DEN) treatment to analyse short-term DEN responses in fibrotic liver.
Methods
Mice
Mice were hosted in individually ventilated cages under standard conditions (12L:12D photo-
period) and received water and a standard rodent diet ad libitum. The animals were monitored
daily, and special care was taken to observe any signs of abnormalities (i.e. marked weight loss
or altered behaviour), which did not appear.
This study was carried out in strict accordance with all relevant welfare regulations and the
Animal Care and Use Committee for Saarland University. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the Landesamt für Verbraucherschutz,
Saarbrücken, Saarland; Permit Number: TV22/2008 and TV36/2011). To generate ABCB4-/-:
TLR4+/+ and ABCB4-/-:TLR4-/- mouse lines respectively, ABCB4-deficient mice on the FVB/NJ
background (strain #002539, The Jackson Laboratory) were crossed to strains C3H/HeN
(TLR4-susceptible, Charles River) and C3H/HeJ (TLR4-deficient, strain #000659, The Jackson
Laboratory) for more than 10 generations. All animals developed normal, and no mortality or
illness was observed. Genotyping of the Abcb4 allele was carried out as described [31]. The
mutated Tlr4 allele of C3H/HeJ was detected by allelic discrimination using a SNP assay for
rs3023006 (Life Technologies). SNP genotyping was carried out on the Taqman1 7500 Fast
Real-Time PCR System (Life Technologies).
For modelling short-term DEN responses, individual mice (n = 12 per line; 6 males, 6
females) were injected intraperitoneally with a single dose of diethylnitrosamine (DEN; 100
mg/kg body weight, Sigma-Aldrich) [32]. After 48 hours, mice were sacrificed and compared
to untreated controls (n = 6 per line; 3 males, 3 females). Again, all mice behaved normal and
did not show any signs of distress upon DEN administration. For sacrifice, mice were submit-
ted to an overdose of isoflurane.
To study of the effects of gut sterilization on HCC development, mice (n = 6) received a
combination of ampicillin (1 g/l), neomycin (1 g/l), metronidazole (1 g/l) and vancomycin
(500 mg/l) in drinking water after DEN challenge (at the age of 2 weeks) for 24 weeks as
described [21].
Chemical assays
For determination of plasma alanine aminotransferase (ALT) activities, blood was taken prior
to DEN injection and after sacrifice. After centrifugation, plasma ALT activities were measured
with an Olympus AU400 chemistry analyzer, using adapted reagents provided by Olympus
[31].
The quantification of hepatic collagen contents was performed in liver hydrolysates via pho-
tometric measurement of the collagen-specific amino acid hydroxyproline as described [33,34].
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Immunohistochemistry
Apoptotic cells were analysed using the Apoptag1 Peroxidase In Situ Apoptosis Detection Kit
(TUNEL method; Millipore). In brief, paraffin slides were deparaffinised in a descending alco-
hol series, treated with proteinase K and H2O2, and incubated with Tdt enzyme at 37°C for one
hour. Afterwards, slides were washed and treated with peroxidase. Apoptotic cells were visual-
ized with AEC (DAKO), counter stained with haematoxylin, and covered with AquaTex1
(Merck).
For proliferation analyses, paraffin sections were deparaffinised, treated with H2O2 and cit-
rate buffer (0.1M, microwave, 25 min), and incubated with a monoclonal rat Ki67 antibody
(4°C o/n, 1:100; DAKO). Secondary antibody (biotinylated-rabbit-anti-rat, 1:100; DAKO) and
ABC complex (Vectastain) were applied thereafter, and Ki67 positive cells were visualized in
the same way as TUNEL positive cells.
For each assay, two slides per animal were stained, and five representative high power fields
(HPFs; 40× magnification) per section were evaluated using LAS Software (Leica DM5000B).
Positively stained cells were counted, and the relative frequency was determined as the mean in
five HPFs.
Gene expression analyses
RNA from snap-frozen livers was isolated using RNeasy Mini Kit (Qiagen). One μg of RNA
was transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Life Tech-
nologies). Expression of Collagen 1α1 (Col1a1; Mm00801666_g1), α-Smooth muscle actin (a-
SMA; Mm_00725412_s1), Interleukin 6 (ll6; Mm00446191_m1) and C-reactive protein (Crp;
Mm00432680_g1) was carried out on the Taqman1 7500 Fast Real-Time PCR System. Gapdh
(Mm99999915_g1) served as endogenous control. Results were evaluated using the ΔΔCT
method and normalised to controls.
Statistical analyses
Data are presented as means ± SEM. Statistical analyses were carried out using SPSS 20.0 and
GraphPad Prism 5.03 software. One-way ANOVA or t-test, respectively, was performed and p-
values< 0.05 were considered as statistically significant.
Results
TLR4 deficiency and biliary fibrosis
The effect of TLR4 on the development of hepatic fibrosis has so far been investigated in artificial
models only with fibrosis induced by chemicals (CCl4, TAA) or surgery (BDL). To analyze the
effect of TLR4 in a more representative model of human liver fibrosis, ABCB4-deficient mice were
crossed into the TLR4-deficient background to obtain double-deficient animals. The resulting
ABCB4-/-:TLR4+/+ and ABCB4-/-:TLR4-/- lines were compared with respect to fibrosis severity.
Panel A of Fig 1 displays that ABCB4-deficient mice lacking TLR4 show significantly less
hepatic collagen accumulation compared to ABCB4-deficient/TLR4-sufficient mice, as mea-
sured by the amounts of the collagen-specific amino acid hydroxyproline. The difference
between strains ABCB4+/+:TLR4+/+ and ABCB4-/-:TLR4+/+ is more marked than between
ABCB4+/+:TLR4-/- and ABCB4-/-:TLR4-/- mice, consistent with the modulation of disease
severity by TLR4. Col1a1mRNA levels are most strongly elevated in the double-deficient mice
(Fig 1B), pointing to differences in post-translational modification and/or collagen composi-
tion between mouse lines. There are no significant differences in a-Sma expression in the four
strains, implicating only a mild effect of TLR4 on this parameter (Fig 1C). Whereas hepatic
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CrpmRNA levels are significantly lower (Fig 1D), Il6 expression levels are elevated signifi-
cantly, consistent with a higher IL6-dependent inflammatory response in the absence of TLR4
(Fig 1E). Plasma ALT activities are significantly higher in the double-deficient mice (Fig 1F).
Also, apoptosis and proliferation rates are increased significantly (Fig 1G and 1H). Taken
together, these findings indicate moderately reduced fibrosis but a higher inflammatory
response in livers from TLR4-deficient ABCB4 knockout mice.
TLR4 deficiency protects healthy liver against DEN-induced liver injury
To analyze the role of TLR4 in short-term DEN treatment in healthy liver, TLR4-sufficient
C3H/HeN and TLR4-deficient C3H/HeJ mice were treated with a single dose of DEN for 48
Fig 1. Fibrosis progression depends on TLR4 status. ABCB4-deficient, ABCB4/TLR4-double-deficient and the corresponding control mice were
compared with respect to hepatic damage and fibrosis at 16 weeks of age when fibrosis is already established (n = 6 per line; 3 males, 3 females). (A)
Hepatic collagen contents, measured as μg hydroxyproline (HYP) per g liver. (B) Relative hepaticCol1a1mRNA expression. ABCB4+/+:TLR4+/+ mice were
set as 1. (C) Relative hepatic a-SmamRNA expression. ABCB4+/+:TLR4+/+ mice were set as 1. (D) Relative hepaticCrpmRNA expression. ABCB4+/+:
TLR4+/+ mice were set as 1. (E) Relative hepatic Il6mRNA expression. ABCB4+/+:TLR4+/+ mice were set as 1. (F) Plasma alanine aminotransferase (ALT)
activities, measured in units per liter (U/l). (G) Hepatocellular apoptosis rates. (H) Hepatocellular proliferation rates. *p < 0.05.
doi:10.1371/journal.pone.0158819.g001
TLR4 Deficiency in Liver Disease
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hours at the age of 16 weeks and compared to untreated controls [32]. Upon DEN challenge,
plasma ALT activity, as an indicator of acute liver injury, increases in both strains, with
TLR4-sufficient mice showing significantly higher ALT levels in comparison to TLR4-deficient
animals (Fig 2A). As a characteristic of acute liver injury, apoptosis and proliferation rates
were determined. Apoptosis increases after DEN treatment in both strains, with the TLR4-defi-
cient strain showing significantly less TUNEL-positive cells as compared to TLR4-sufficient
mice, reflecting ameliorated liver damage in the absence of TLR4 (Fig 2B). Proliferation was
equally affected, since TLR4-sufficient animals display significantly increased proliferation
rates after DEN injection in comparison to TLR4-deficient mice (Fig 2C). Hepatic expression
of Il6, as a marker for the inflammatory response, is augmented in DEN-treated mice, but there
is no difference with respect to TLR4 status (Fig 2D). Although Crp expression is not signifi-
cantly affected by DEN, TLR4-deficient mice show the lowest Crp levels (Fig 2E).
TLR4 modulates the response to DEN in injured liver
As HCC formation usually occurs on a fibrotic background, we combined the two mouse mod-
els, ABCB4/TLR4-deficiency and short-term DEN treatment. TLR4-sufficient and TLR4-defi-
cient ABCB4 knockout mice were treated with DEN at 7 weeks (pre-fibrotic stage; Fig 3) and
16 weeks of age (established fibrosis; Fig 4), as described in Methods. At the early time-point,
liver damage (as assessed by ALT levels; Fig 3A) is not altered. Col1a1mRNA levels are signifi-
cantly elevated in the double-deficient mice (Fig 3B), whereas a-Sma expression does not differ
(Fig 3C). The inflammatory response (as indicated by hepatic Il6 expression; Fig 3D) is not
Fig 2. DEN-induced liver injury is reduced in the absence of TLR4. TLR4- sufficient and deficient animals at the age of 16 weeks were subjected to DEN
for 48 hours (DEN, n = 12 per line; 6 males, 6 females) and compared to untreated controls (CON; n = 16per line; 3 males, 3 females). (A) Plasma ALT
activities, measured in U/l. (B) Hepatocellular apoptosis rates. (C) Hepatocellular proliferation rates. (D) Relative hepatic Il6 expression. Untreated
TLR4-sufficient mice were set as 1. (E) Relative hepaticCrp expression. Untreated TLR4-sufficient mice were set as 1. **p<0.01.
doi:10.1371/journal.pone.0158819.g002
TLR4 Deficiency in Liver Disease
PLOS ONE | DOI:10.1371/journal.pone.0158819 July 8, 2016 6 / 12
affected. However, panels E and F of Fig 3 illustrate that ABCB4/TLR4 double-deficient mice
show higher apoptosis and proliferation rates, respectively, after DEN treatment in comparison
to ABCB4 knockout mice.
In the congenic mouse lines with liver fibrosis at 16 weeks of age, ALT activities and apopto-
sis rates are not significantly changed (Fig 4A and 4F). Col1a1 expression increases in the dou-
ble-deficient mice (Fig 4B) while a-SmamRNA levels remain constant (Fig 4C).
In contrast, Il6 and CrpmRNA levels are lower as compared to ABCB4 deficient mice with
normal TLR4 status (Fig 4D and 4E). Also, proliferation rates are significantly decreased in
ABCB4/TLR4 double-deficient mice (Fig 4G).
Selective digestive tract decontamination reduces tumor growth
To model the effects of TLR4 deficiency on HCC development, we sterilized the gut with a
cocktail of antibiotics in ABCB4-deficient mice after DEN treatment (Fig 5A). The use of anti-
biotics lead to reduced tumor growth and significantly lower tumor numbers, indicating that
HCC development is promoted by intestinal bacteria (Fig 5B and 5C).
Discussion
As a modulator of innate immunity and LPS response, TLR4 has been widely implicated in var-
ious liver disorders including liver fibrosis and hepatocellular carcinoma [8,11]. Many studies
linked TLR4 activity to enhanced fibrosis but all of these experiments were performed using
chemical or surgical models [20]. In this study, we aimed to set up a preferable
Fig 3. TLR4 deficiency increases apoptosis and proliferation at early fibrotic stages. ABCB4-deficient and ABCB4/TLR4-double-deficient mice were
subjected to DEN at 7 weeks of age (n = 12 per line; 6 males, 6 females). (A) Plasma ALT activities, measured in U/l. (B) Relative hepaticCol1a1mRNA
expression. ABCB4-/-:TLR4+/+ mice were set as 1. (C) Relative hepatic a-SMAmRNA expression. ABCB4-/-:TLR4+/+ mice were set as 1. (D) Relative hepatic
Il6 expression. ABCB4-/-:TLR4+/+ mice were set as 1. (E) Hepatocellular apoptosis rate. (F) Hepatocellular proliferation rate. *p < 0.05.
doi:10.1371/journal.pone.0158819.g003
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pathophysiological situation, which allows us to better assess the role of TLR4 in hepatic fibro-
sis and pre-cancerogenous liver injury. We took advantage of C3H/HeJ mice that carry a loss-
of-function mutation in the Tlr4 gene [30] and ABCB4 knockout mice that develop biliary
fibrosis [28], and generated congenic ABCB4-deficient mice with and without TLR deficiency.
ABCB4-deficient mice lacking TLR4 show increased liver damage, hepatic inflammatory
response (Il6 expression), apoptosis and proliferation as compared to ABCB4 knockout mice
sufficient for TLR4. This imbalance in "liver tolerance" has been linked to TLR4 before [10,11].
Interestingly, although liver damage and cell division/death are more prominent in the double-
deficient line, hepatic collagen contents as marker for liver fibrosis are reduced, implicating a
Fig 4. TLR4 deficiency protects against DEN-induced liver injury in fibrotic liver. ABCB4-deficient and ABCB4/TLR4-double-deficient mice were
subjected to DEN at 16 weeks of age (n = 12 per line; 6 males, 6 females). (A) Plasma ALT activities, measured in U/l. (B) Relative hepaticCol1a1mRNA
expression. ABCB4-/-:TLR4+/+ mice were set as 1. (C) Relative hepatic a-SMAmRNA expression. ABCB4-/-:TLR4+/+ mice were set as 1. (D) Relative hepatic
Il6 expression. ABCB4-/-: TLR4+/+ mice were set as 1. (E) Relative hepaticCrp expression. ABCB4-/-:TLR4+/+ mice were set as 1. (D) Hepatocellular
apoptosis rate. (E) Hepatocellular proliferation rate. *p<0.05; **p<0.01.
doi:10.1371/journal.pone.0158819.g004
TLR4 Deficiency in Liver Disease
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beneficial role for TLR4 in liver injury but not in liver fibrosis in this model. This differential
role of TLR4 might be due to interaction with the pre-existing liver disease (ABCB4
deficiency).
Fig 5. Gut sterilization leads to reduced tumor growth. ABCB4-deficient mice underwent DEN treatment and received a combination of
four antibiotics (Abx) in drinking water until sacrifice (SAC). (A) Experimental design. (B) Macroscopic appearance of livers from
ABCB4-deficient mice with or without Abx treatment. (C) Tumor sizes and numbers in the two experimental groups (-ABx: n = 10; +ABx:
n = 6). *p<0.05.
doi:10.1371/journal.pone.0158819.g005
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As established by Naugler et al. acute liver injury can be modeled by a single dose of DEN
for 48 hours [32]. In this study the authors describe IL6-dependent gender-specific differences
in response to DEN. Interestingly we only detected gender disparity in ALT activity (S1 Fig) in
our different models, all other parameters measured showed no significant differences between
male and female mice (data not shown).
The roles of TLR4 in liver cancer have been analyzed in several studies showing an inhibi-
tory effect on HCC initiation in the DEN model [35] and HCC promotion in a combined
model of CCl4 and DEN [21]. In our study we could show that in the absence of TLR4, liver dam-
age, apoptosis and proliferation after DEN challenge are decreased, indicating that TLR4 pro-
motes DEN-induced liver injury in mice and that the inactivation of TLR4 is advantageous in
this setting. Nevertheless, Wang et al. (36) showed a protective role of TLR4 in a long-term DEN
model in TLR4-deficient and wild-type mice. These mice were injected shortly after birth without
pre-damaged liver. This might explain our beneficial role of TLR4 in our combined ABCB4/
TLR4-deficiency model as the carcinogenic stimulus is brought to an already injured liver.
In the third part of our study, mice lacking ABCB4 and TLR4 were subjected to DEN at two
defined points in time (pre-fibrosis and established fibrosis) to assess the situation of hepatic injury
in a fibrotic liver. At seven weeks of age, only minor alterations are present in livers of ABCB4-defi-
cient mice [24,25]. In our model no differences with respect to liver damage and inflammatory
response are apparent, while apoptosis and proliferation rates are increased in ABCB4-/-:TLR4-/-
double-deficient animals as compared to congenic ABCB4-/-:TLR4+/+ mice. This observation indi-
cates that TLR4 modifies the hepatocellular response at this early stage and is consistent with the
notion that TLR4 deficient mice display increased apoptosis in non-tumorous liver tissue [21].
Later at 16 weeks of age when biliary fibrosis is established in ABCB4 knockout mice, the
additional ablation of TLR4 leads to lower proliferation rates, while apoptosis tends to be ele-
vated in the short-term DENmodel; as expected, inflammatory markers are also decreased.
These changes should have beneficial effects on hepatocytes, as unlimited division capacity and
reduced programmed cell death are hallmarks of cancer [36]. The results are also consistent
with reduced expression of the antiapoptotic genes Birc3, Birc5 and Nos2 in livers from TLR4-/-
mice suggesting that TLR4 mediates survival ligands to tumor initiating cells [21].
Since TLR4 deficiency showed protective effects in our model, we additionally analyzed the
effect of gut sterilization after HCC induction by DEN in ABCB4-deficient mice. This model
resembled the findings in TLR4-deficient mice, with the reduction of HCC number in gut ster-
ilized mice fitting to the observations in our genetically modified mice as well as other reports
in experimental HCC models [35,37,38].
As C3H/HeJ and C3H/HeN inbred strains are kept separately since 1974 when C3H/HeN
came to Europe we certainly cannot exclude that other genetic differences apart from Tlr4may
contribute to our results but taken together, our study supports the hypothesis that TLR4 plays
an important role in both hepatic fibrosis and DEN-induced liver injury. TLR4 deficiency exerts
beneficial effects on liver fibrogenesis, as indicated by reduced hepatic collagen accumulation in
ABCB4-/-:TLR4-/- double-deficient mice. In addition, the absence of TLR4 has protective effects
against pre-cancerogenous events in cholestatic liver injury, pointing to new avenues for the pre-
vention and therapy of cancer in ABCB4 deficiency and related cholestatic liver diseases.
Supporting Information
S1 Fig. ALT activities divided by sex. Results of Figs 1F(A), 2A(B) and 4A(C) itemized by sex
(m: male, f: female).(A) Plasma ALT activities, measured in U/l of ABCB4-deficient and
ABCB4/TLR4-double-deficient mice. (B) Plasma ALT activities, measured in U/l of TLR4- suf-
ficient and deficient animals at the age of 16 weeks with (DEN) and without (CON) DEN
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challenge. (C) Plasma ALT activities, measured in U/l of ABCB4-deficient and ABCB4/
TLR4-double-deficient mice subjected to DEN at 16 weeks of age. p<0.05.
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